Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand?
- 313 Downloads
The definition of remission in Crohn’s disease and ulcerative colitis has evolved to include mucosal healing as a measure of treatment efficacy. Randomized, controlled trials have demonstrated mucosal healing is attainable with the current arsenal of therapies available to treat inflammatory bowel disease. Mucosal healing has been shown to reduce the likelihood of clinical relapse, reduce the risk of future surgeries, and reduce hospitalizations. This review focuses on the latest studies addressing clinical outcomes of mucosal healing in the clinical trial and practice setting.
KeywordsCrohn’s disease Ulcerative colitis Mucosal healing
Conflicts of interest: Dr. Ha, none. Dr. Kornbluth has received grant or research support from Salix, Centocor, Abbott, UCB, and Osiris; served as consultant or scientific advisor to Salix, Shire, Centocor, Given Imaging, Prometheus, UCB, Abbott, Takeda, Alaven, Warner-Chilcott, and Axcan; and served on speakers’ bureaus for and received honoraria from Salix, Prometheus, Abbott, UCB, Axcan, Warner-Chilcott, and Centocor.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Cellier C, Sahmoud T, Froguel E, et al.: Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994, 35:231–235.CrossRefPubMedGoogle Scholar
- 9.• D’Haens G, Sandborn WJ, Feagan BG, et al.: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763–786. This article summarizes the disease activity indices in ulcerative colitis, highlighting the variable endoscopic features of the scoring systems used in the major ulcerative colitis clinical trials.Google Scholar
- 24.•• Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al.: Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7:15–29. This article comprehensively reviews the definitions and scoring systems for mucosal healing and summarizes the evidence-based studies of the current arsenal of medications and their ability to achieve mucosal healing.Google Scholar
- 27.Sandborn WJ, Regula J, Feagan BG, et al.: Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009, 137:1934–1943 e1931–1933.Google Scholar
- 34.Reinisch W, Sandborn WJ, Hommes DW, et al.: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. Gastroenterology 2010, 138:S114–S115.Google Scholar
- 39.• D’Haens G, Baert F, van Assche G, et al.: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008, 371:660–667. This study demonstrated significantly greater rates of mucosal healing at week 104 in the early combined immunosuppresion group compared to the conventional therapy arm, even though clinical remission rates were similar.Google Scholar
- 41.Van Moerkercke W, Ackaert C, Compernolle G, et al.: High infliximab trough levels are associated with mucosal healing in Crohn’s disease. Gastroenterology 2010, 138:S60.Google Scholar
- 42.•• Colombel JF, Sandborn WJ, Reinisch W, et al.: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010, 362:1383–1395. This randomized, controlled trial of biologic- and immunomodulator-naïve Crohn’s disease patients with moderate to severe symptoms demonstrated greater clinical response and mucosal healing with combination infliximab and azathioprine compared to infliximab or azathioprine monotherapy.Google Scholar
- 45.Colombel J-F, Rutgeerts PJ, Sandborn WJ, et al.: Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn’s disease: results from EXTEND. Gastroenterology 2010, 138:S518.Google Scholar
- 46.Colombel J-F, Lemann M, Bouhnik Y, et al.: Endoscopic mucosal improvement in patients with active Crohn’s disease treated with certolizumab pegol: week 10 and 54 results of the MUSIC trial. Gastroenterology 2010, 138:S166.Google Scholar
- 47.•• Schnitzler F, Fidder H, Ferrante M, et al.: Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009, 15:1295–1301. This study assessed the long-term outcomes of mucosal healing with infliximab treatment. The authors found Crohn’s disease patients with mucosal healing had sustained clinical benefit of infliximab, fewer major abdominal surgeries and hospitalizations.Google Scholar
- 48.Rutgeerts PJ, Reinisch W, Thakkar R, et al.: Early mucosal healing status predicts long-term clinical benefits for adalimumab-treated patients with moderate to severe Crohn’s disease. Gastroenterology 2010, 138:S85.Google Scholar
- 49.Rutgeerts P, Geboes K, Camez A, et al.: Quality of life improvements in adalimumab-treated patients with mucosal healing: results from the EXTEND trial. Am J Gastroenterol 2009, 104:S461.Google Scholar
- 59.•• Baert F, Moortgat L, Van Assche G, et al.: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010, 138:463–468. This study was the 2-year follow-up of the D’Haens study of early combined immunosuppression versus conventional therapy in the treatment of Crohn’s disease. The authors found complete mucosal healing predicted sustained steroid-free remission up to four years after steroid enrollment.Google Scholar
- 60.Louis E, Vernier-Massouille G, Grimaud J-C, et al.: Infliximab discontinuation in Crohn’s disease patients in stable remission on combination therapy with immunosuppressors: a propsective ongoing cohort study. Gastroenterology 2009, 136:A146.Google Scholar
- 64.Sorrentino D, Paviotti A, Terrosu G, et al.: Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn’s disease. Clin Gastroenterol Hepatol 2010, 8:591–599 e591.Google Scholar
- 68.Ordas I, Garcia-Bosch O, Rodriguez S, et al.: Validation of a magnetic resonance index of activity for ileocolonic Crohn’s disease. Gastroenterology 2010, 138:S75.Google Scholar
- 69.Horjus CS, Bruijnen R, de Jong D, et al.: Magnetic resonance enterography in the assessment of the disease activity in Crohn’s disease: a retrospective study. Gastroenterology 2010, 139:S527.Google Scholar